Kuros Biosciences AG

Equities

KURN

CH0325814116

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:10 2024-05-10 am EDT			5-day change	1st Jan Change
7.15 ^CHF	+8.33%		+7.20%	+104.87%

Apr. 24	Kuros Biosciences Posts Higher Q1 Product Sales	MT
Apr. 17	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2021

March 16, 2022 at 02:00 am EDT

Kuros Biosciences AG reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was CHF 13.82 million compared to CHF 4.04 million a year ago. Net loss was CHF 7.54 million compared to CHF 11.52 million a year ago.

Basic loss per share from continuing operations was CHF 0.23 compared to CHF 0.47 a year ago.

Latest news about Kuros Biosciences AG

Kuros Biosciences Posts Higher Q1 Product Sales	Apr. 24	MT
Kuros Biosciences AG Approves Board of Director and Committee Changes	Apr. 17	CI
Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up	Mar. 13	MT
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
US FDA Approves Kuros Biosciences' Bone Graft Granules for Interbody Use	Jan. 31	MT
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand	Jan. 31	CI
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	Jan. 04	CI
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	Dec. 27	CI
US FDA Approves Kuros Biosciences' Fibrillar Collagen Matrix Bone Graft Substitute for Interbody Applications	Nov. 29	MT
Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages	Nov. 28	CI
Kuros Biosciences Appoints CEO Amid Executive Management Shake-up	23-10-12	MT
Kuros Biosciences Reports Jump in Nine-month Medical Devices Sales	23-10-12	MT
Kuros Biosciences Books Greater Loss; Revenue Grows	23-08-09	MT
Kuros Biosciences AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-29	CI
Kuros Biosciences Completes Patient Enrollment for Degenerative Disc Disease Drug Trial	23-07-14	MT
Kuros Biosciences Interim CFO Named to Role Permanently	23-04-27	MT
Kuros Biosciences' Medical Devices Sales Grow in Q1	23-04-27	MT
Kuros Biosciences AG Appoints Daniel Geiger as Chief Financial Officer	23-04-27	CI
Kuros Biosciences Net Loss Widens in FY22	23-03-15	MT
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Kuros Biosciences Appoints Interim CFO	23-02-17	MT
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer	22-12-02	CI
Kuros Biosciences Concludes Initial Patient Enrollment in Mid-stage Study of Bone Graft	22-11-23	MT
Kuros Biosciences Finalizes Enrolment In Early-stage Study Of MagnetOs Granules	22-11-02	MT

Chart Kuros Biosciences AG

Duration

Period

More charts

Company Profile

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KUROS BIOSCIENCES AG	+104.87%	291M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs